Social Security won't be able to pay full benefits in 2034 if Congress doesn't act
Social Security will not be able to fully pay monthly benefits to tens of millions of retirees and people with disabilities in 2034 if lawmakers don't act to address the program's pending shortfall, according to an annual report released Wednesday by Social Security's trustees.
The combined Social Security trust funds – which help support payments to the elderly, survivors and people with disabilities – are expected to be exhausted in 2034, one year earlier than previously forecast, according to the trustees' annual report. At that time, payroll tax revenue and other income sources will only be able to cover 81% of benefits owed.
The deterioration in the forecast stems from several factors, including a law passed by Congress last year that increased benefits for certain workers and the trustees' assumption that it will take longer for the nation's fertility rate to recover from historically low levels. Average earnings are expected to grow somewhat more slowly over the coming decade, according to the report.
Medicare's fiscal outlook also worsened. Its hospital insurance trust fund, known as Medicare Part A, is expected to be able to cover scheduled inpatient hospital benefits until 2033, compared to 2036 in last year's report from the program's trustees. At that time, Medicare will only be able to pay 89% of total scheduled Part A benefits, which also cover hospice care, short-term skilled nursing facility services and home health services following hospitalizations.
The program's trustees project that Medicare's trust fund will be drained sooner because of increased medical spending in 2024, which also raised the forecast for future expenditures. Plus, the trustees raised their assumed growth level of inpatient and hospice services in coming years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Following reported suicide attempt, Augusta County businessman's sentencing rescheduled
This story discusses the possibility of suicide. If you or someone you know is struggling or in crisis, help is available. Call or text 988 or chat at Sentencing in a federal tax case for an Augusta County businessman convicted of defrauding the IRS is back on track after a reported suicide attempt last month likely derailed a trip to prison. Richard Moore, 47, of Fishersville, was indicted in December 2021 on multiple charges, but the government said he continued to bilk the IRS even after being indicted. Moore is the former vice president of Nexus Services Inc., a company that was once headquartered in Verona. Moore was supposed to be sentenced the morning of May 29 in United States District Court in Harrisonburg. But Moore didn't show after an online post that same day appeared to indicate he was preparing to commit suicide. Court records state he did not attend the hearing "due to a health-related matter." Sentencing has been rescheduled for July 21, online records show. In January, Moore pleaded guilty to two counts of tax fraud in federal court after failing to pay the IRS more than $3.1 million in trust fund taxes while he managed the finances at Nexus, where he was also once a part-owner. For numerous quarters, beginning around 2015 and through the first quarter of 2024, Moore withheld tax funds but did not pay them over to the IRS and did not file returns, according to the justice department. Nexus, hit with an $811 million judgement last year in a federal lawsuit that included Moore and his husband, Mike Donovan, provided bond securitization for immigrants held or released from U.S. Immigration and Customs Enforcement. More: Nexus owners accused of stealing $426,000 from brother of Florida school shooter In a sentencing memorandum filed by Trial Attorney William M. Montague of the Justice Department's Tax Division, it states he wants Moore behind bars for a decade. Montague said the cash that Moore did not turn over to the IRS was used, in part, to fund a lavish lifestyle that included a fleet of several sports sports cars, $322,000 for the band Fall Out Boy to perform at a birthday party, $1 million for a book by his husband that used a ghostwriter, and more than a half-million dollars for his wedding to Donovan. Montague said Moore went through more than $11 million the past decade or so to keep up his lavish lifestyle. Moore's attorney, Mario Williams, who is seeking a probationary sentence of five years, said his client was overwhelmed by his duties at Nexus. "In 2014, Nexus started to grow at a startling pace. Mr. Moore had no professional training or expertise and managing the financial affairs of the company quickly became more than he could handle," Williams said in his sentencing memorandum. "Simply put, he was way over his head. Allowing that Mr. Moore was ill-equipped to perform increasingly complex financial management is not to excuse him for failing to file returns and pay over tax trust funds in a consistent and lawful manner, but it does explain how the problem snowballed out of control." Court records show Moore remains free on bond. Moore is also facing charges in a $426,000 theft case in Augusta County, and will go on trial in September. More: Carilion Clinic Family Medicine in Weyers Cave is closing. What we know Brad Zinn is the cops, courts and breaking news reporter at The News Leader. Have a news tip? Or something that needs investigating? You can email reporter Brad Zinn (he/him) at bzinn@ You can also follow him on X (formerly Twitter). This article originally appeared on Staunton News Leader: Sentencing hearing set once again for Augusta County businessman
Yahoo
7 minutes ago
- Yahoo
Watch live: Fed Chair Jerome Powell holds press conference after interest rate decision
Fed Chair Jerome Powell is speaking with reporters after the Federal Reserve's June 18 decision to hold interest rates steady, as expected. Investors and analysts are looking for any indications on the Fed's path for the rest of 2025. The meeting also featured the latest release of the Fed's "dot plot," a chart that shows each Fed official's prediction about the direction of the central bank's benchmark interest rate. This chart is updated quarterly, and the last version came out in March. The dot plot showed most officials still expect two rate cuts by the end of 2025. Powell is likely to add context to how economic uncertainty tied to President Trump's tariffs and the geopolitical conflict in the Middle East have affected the Fed's outlook. See more on the Fed's decision. Watch the press conference live above. Click here for in-depth analysis of the latest stock market news and events moving stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Lilly to acquire Verve in $1B bet on gene editing for heart disease
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eli Lilly agreed to buy Verve Therapeutics for $1 billion, betting on the promise of one-and-done gene therapies to treat cardiovascular disease. The deal announced Tuesday offers Verve stockholders $10.50 a share, plus a contingent value right worth another $3 a share. The non-tradeable CVR would pay out if the company's experimental VERVE-102 treatment advances enough to dose a patient in a Phase 3 trial within 10 years of the transaction's closing. Verve CEO Sekar Kathiresan and other top stockholders have already agreed to tender shares that represent about 17.8% of Verve's outstanding stock and the gene editing company's board recommends that all investors agree to the tender offer, Lilly said. A second-step merger will follow if needed. The companies expect to complete the transaction in the third quarter. For Lilly, the acquisition offers greater control of a pipeline it's already invested in. The company inked a deal with Verve in 2023 to develop a product now known as VERVE-301 that's still in preclinical research. Later that year, Lilly bought other Verve opt-in rights from Beam Therapeutics that include the program for VERVE-102. 'The deal makes sense for Verve shareholders and makes sense given the exposure Lilly has to Verve's entire disclosed pipeline,' William Blair analyst Myles Minter wrote in a note to clients. Lilly is also stepping in at a time when Verve shares are undervalued, Minter said. Verve went public in 2021 with one of the largest initial offerings of the year in the biotech industry, raising almost $270 million by selling shares at $19 each. As an investment boom continued that year amid high hopes for gene therapies, Verve's shares soared above $70. But the company's lead product, VERVE-101, encountered safety concerns and Verve decided to scrap it in favor of a successor, VERVE-102, that used a different lipid nanoparticle for delivery of the treatment. That product has shown early promise. Even so, Verve shares closed at $6.27 yesterday, hurt by a general slump in investment in cell and gene therapy companies. 'Eli Lilly is getting a bargain here,' Minter wrote. Still, the 67% premium to the current share price is 'a win for Verve shareholders and the gene editing space more broadly, which has been under significant macro pressure in a difficult funding environment.' The CVR is likely to pay out, Minter said. The timeframe of 10 years shouldn't be an issue; dosing in a Phase 3 trial is more dependent on continued demonstration of safety in earlier-stage research, he wrote. The larger question for Lilly is whether patients and doctors will embrace genetic medicines for cardiovascular disease, when more traditional treatment options are readily available. Other companies have struggled in that situation. Verve counters that many patients drop off standard medications, putting themselves in danger of complications like a heart attack. The company's lead product is administered as an infusion, which also sets it apart from the complicated administration process that underlies high-profile gene editing treatments such as Vertex's Casgevy. Verve's medicine 'could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,' Ruth Gimeno, Lilly's group vice president for diabetes and metabolic research and development, said in the company's press release. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
